Hormonal
Metformin use is associated with reduced cancer incidence and mortality in diabetic patients, with specific benefits observed in HER2-positive breast cancer and prostate cancer recurrence.
If you have type II diabetes, metformin is a standard treatment that may also offer protective benefits against certain cancers. Discuss with your doctor if metformin is appropriate for you, especially if you have a family history of breast or prostate cancer. Do not take metformin solely for cancer prevention if you do not have diabetes.
metformin has been associated with reduced total cancer incidence... and with decreased cancer-specific mortality... metformin use was associated with reduced breast cancer incidence and mortality... metformin use was associated with reduced risk of recurrence following primary therapy [prostate cancer]
Why this rating
Evidence is mixed across studies, with some showing protective effects and others null findings, particularly in non-diabetic or insulin-sensitive populations.
Source
Obesity and cancer: mechanistic insights from transdisciplinary studies
Emma H. Allott et al. · Endocrine Related Cancer · 2015
DOI 10.1530/erc-15-0400
More from this paper
- Diet-induced obesity promotes tumor growth and progression in breast and prostate cancer models, whereas calorie restriction (CR) slows tumor growth and increases tumor latency.Good
- Obesity is associated with delayed cancer diagnosis and reduced treatment efficacy due to screening biases, technical challenges, and altered drug metabolism.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →